Search
United Therapeutics Corp
UTHRAdd to Watchlist
598.720USD
+5.180+0.87%
Close 10-30 16:00（ET）
25.68BMarket Cap
20.44P/E TTM
Today
+0.87%
5 Days
+1.91%
1 Month
+10.49%
6 Months
+4.79%
Year to Date
+22.88%
1 Year
+34.41%
Key Figures
600.000Open
608.050High
42.00KVolume
20.44P/E TTM
18.64P/E Dynamic
--Dividend TTM
0.10%Turnover Ratio
593.540Prev. Close
589.615Low
25.22MTurnover
21.48P/E Static
4.01P/B
0.00%Div Yield TTM
17.81%ROA
609.35052wk High
0.07Volume Ratio
1.20BNet Profit
42.89MShares
29.2723EPS TTM
0.58Beta
20.26%ROE
430.02052wk Low
3.11%Amplitude
87.30%Gross Margin
25.68BMarket Cap
-3.05Reward/Risk
2.16%Risk Rate
Recent
Earnings
United Therapeutics Corp Stock (UTHR) Moved Up by 7.26% on Oct 1: What Investors Need To Know
• Court ruled for United Therapeutics, confirming patent validity against Liquidia. • Analysts upgraded ratings after the legal victory secured market exclusivity. • The company initiated an accelerated share repurchase to reduce shares.
TradingKeyThu, Oct 1
United Therapeutics Corp Stock (UTHR) Moved Up by 12.20% on Sep 30: Key Drivers Unveiled
• United Therapeutics executed an accelerated share repurchase agreement to complete its buyback program. • The FDA accepted filings for nebulized Tyvaso and ralinepag for regulatory review. • The company reported an annual revenue of $3.18B and net profit of $1.33B.
TradingKeyWed, Sep 30
United Therapeutics Corp's Score
0.04vs previous score
Forecast8.13
Financial Health9.22
Technical3.80
Valuation Dimensions8.24
Institutional Confidence10.00
Risk Assessment8.27
Media Coverage
Coverage Level
Very Low
Very High
Positive+
Analyst Rating
United Therapeutics Corp Technical Analysis
Technical Indicators
Strong buy
Summary
Buy
Moving Average
Strong buy
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
2026-11-04
Reporting Period
2026Q2
Earnings / Forecast
7.82/6.83
Revenue / Forecast
783.30M/805.65M
United Therapeutics Corp Profile
SectorPharmaceuticals
Ticker SymbolUTHR
Number of employees1305
CountryUnited States of America
Ownership
| Shareholders | Proportion |
|---|---|
| BlackRock Institutional Trust Company, N.A. | 9.75% |
| Avoro Capital Advisors LLC | 6.14% |
| Wellington Management Company, LLP | 5.75% |
| Vanguard Portfolio Management, LLC | 4.72% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 42.28% |
| Investment Advisor/Hedge Fund | 39.53% |
| Hedge Fund | 10.32% |
| Pension Fund | 2.92% |
Related Instruments
+3.19%
-0.73%
+1.41%
+2.18%
-0.19%
+7.02%
+1.15%
+3.06%
+2.20%
+1.90%
+3.50%
+1.78%
+1.40%
+2.81%
+1.71%
+13.33%
-0.47%
+4.50%
-0.24%
-0.55%Popular Instruments
51788.900
-548.500 (-1.05%)
28406.600
-658.400 (-2.27%)
7583.100
-92.600 (-1.21%)
12785.000
-56.000 (-0.44%)
62328.000
-1656.000 (-2.59%)
6120.900
-77.700 (-1.25%)
102.428
+0.026 (+0.03%)
344.630
-4.280 (-1.23%)
204.640
-9.020 (-4.22%)
3874.710
-146.240 (-3.64%)
FAQs
What is the current price of United Therapeutics Corp (UTHR)?
The current price of United Therapeutics Corp (UTHR) is 598.72.
What is the symbol of United Therapeutics Corp?
The ticker symbol of United Therapeutics Corp is UTHR.
What is the 52-week high of United Therapeutics Corp?
The 52-week high of United Therapeutics Corp is 609.35.
What is the 52-week low of United Therapeutics Corp?
The 52-week low of United Therapeutics Corp is 430.02.
What is the market capitalization of United Therapeutics Corp?
The market capitalization of United Therapeutics Corp is 25.68B.
Is United Therapeutics Corp (UTHR) currently rated as Buy, Hold, or Sell?
According to analysts, United Therapeutics Corp (UTHR) has an overall rating of Buy, with a price target of 659.81.
What is the Earnings Per Share (EPS TTM) of United Therapeutics Corp (UTHR)?
The Earnings Per Share (EPS TTM) of United Therapeutics Corp (UTHR) is 29.27.